Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559603 | 0.82 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL21964566 | 0.82 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL23880174 | 0.81 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL28125498 | 0.79 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL7686440 | 0.77 | SMN1; SMN2 (0.44) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL1881388 | 0.76 | TXNRD1 (0.40) | L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL18049571 | 0.76 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL18049623 | 0.76 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL18418903 | 0.76 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1POLBMAPTLMNA | |
| SCHEMBL31074579 | 0.73 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| EP-4046688-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4046688-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-08-24 | — | — | EP | disclosed |
| EP-3267996-B1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| EP-3267996-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144846-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-09-15 | — | — | WO | disclosed |
| CN-102124000-B | Pyridine compounds | ASTRAZENECA AB | 2014-09-17 | — | — | CN | disclosed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| CN-102124000-A | Pyridine compounds | ASTRAZENECA AB | 2011-07-13 | — | — | CN | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | L3MBTL1 547/4885ALDH1A1 1856/4885POLB 1400/4885 |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | L3MBTL1 1305/4885ALDH1A1 2153/4885POLB 1348/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | L3MBTL1 547/4885ALDH1A1 1856/4885POLB 1400/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | L3MBTL1 4279/4885ALDH1A1 2505/4885POLB 3557/4885 |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | L3MBTL1 1305/4885ALDH1A1 2153/4885POLB 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.